Clinical Trial Update: PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial update suggests Prostaglandin E1 may improve coronary microvascular perfusion in patients with coronary artery disease and diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Diabetes Mellitus
• Ischemic Heart Disease

Drugs mentioned

• Prostaglandin E1 (alprostadil)

Snippet

Sponsor: Tongji Hospital | Conditions: Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease | Phase 4 | Status: UNKNOWN